Edgewise Therapeutics (EWTX) EBIT (2020 - 2026)
Edgewise Therapeutics (EWTX) reported EBIT of -$54.1 million for Q1 2026, down 17.75% on a YoY basis from -$65.8 million in Q1 2025, and up 3.33% sequentially from -$56.0 million in Q4 2025.
Edgewise Therapeutics (EWTX) EBIT (2020 - 2026) Analysis & Trends
Edgewise Therapeutics (EWTX) has 7 years of EBIT data on file, last reported at -$54.1 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT fell 17.75% year-over-year to -$54.1 million; the trailing twelve-month figure through Mar 2026 stood at -$199.6 million (down 17.36% YoY), and the FY2025 full-year result was -$191.4 million, down 20.51% from the prior year.
- EBIT rose to -$54.1 million in Q1 2026, from -$56.0 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$14.8 million in Q1 2022 to a low of -$56.0 million in Q4 2025.
- A 5-year average of -$34.7 million and a median of -$34.8 million in 2024 frame the typical range for EBIT.
- Across the five-year window, EBIT tumbled 116.22% in 2022 and fell 11.82% in 2025, its largest moves.
- Tracing EWTX's EBIT over 5 years: stood at -$22.1 million in 2022, then plunged by 53.37% to -$33.9 million in 2023, then sank by 34.49% to -$45.5 million in 2024, then fell by 22.92% to -$56.0 million in 2025, then increased by 3.33% to -$54.1 million in 2026.
- Business Quant data shows EWTX's EBIT at -$54.1 million in Q1 2026, -$56.0 million in Q4 2025, and -$46.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Edgewise Therapeutics | 4.21 Bn | 4.21 Bn | - | -54.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -54.12 Mn |
| Dec 31, 2025 | -55.98 Mn |
| Sep 30, 2025 | -46.86 Mn |
| Jun 30, 2025 | -42.61 Mn |
| Mar 31, 2025 | -45.96 Mn |
| Dec 31, 2024 | -45.54 Mn |
| Sep 30, 2024 | -40.43 Mn |
| Jun 30, 2024 | -38.11 Mn |
| Mar 31, 2024 | -34.75 Mn |
| Dec 31, 2023 | -33.86 Mn |
| Sep 30, 2023 | -29.45 Mn |
| Jun 30, 2023 | -25.34 Mn |
| Mar 31, 2023 | -25.70 Mn |
| Dec 31, 2022 | -22.08 Mn |
| Sep 30, 2022 | -18.26 Mn |
| Jun 30, 2022 | -16.49 Mn |
| Mar 31, 2022 | -14.83 Mn |
| Dec 31, 2021 | -12.82 Mn |
| Sep 30, 2021 | -13.08 Mn |
| Jun 30, 2021 | -10.46 Mn |